vs
Side-by-side financial comparison of IDEAYA Biosciences, Inc. (IDYA) and XBP Global Holdings, Inc. (XBP). Click either name above to swap in a different company.
IDEAYA Biosciences, Inc. is the larger business by last-quarter revenue ($207.8M vs $152.4M, roughly 1.4× XBP Global Holdings, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs -200.7%, a 258.0% gap on every dollar of revenue. IDEAYA Biosciences, Inc. produced more free cash flow last quarter ($142.2M vs $10.5M).
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
IDYA vs XBP — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $207.8M | $152.4M |
| Net Profit | $119.2M | $-305.8M |
| Gross Margin | — | 21.7% |
| Operating Margin | 52.2% | -191.7% |
| Net Margin | 57.4% | -200.7% |
| Revenue YoY | — | -34.7% |
| Net Profit YoY | 330.1% | -980.1% |
| EPS (diluted) | $1.33 | $-2.60 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $207.8M | $152.4M | ||
| Q3 24 | $0 | $233.4M | ||
| Q2 24 | $0 | — | ||
| Q1 24 | $0 | — | ||
| Q3 22 | $29.7M | — |
| Q3 25 | $119.2M | $-305.8M | ||
| Q3 24 | $-51.8M | $-28.3M | ||
| Q2 24 | $-52.8M | — | ||
| Q1 24 | $-39.6M | — | ||
| Q3 22 | $1.6M | — |
| Q3 25 | — | 21.7% | ||
| Q3 24 | — | 18.9% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | — | — |
| Q3 25 | 52.2% | -191.7% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | 2.2% | — |
| Q3 25 | 57.4% | -200.7% | ||
| Q3 24 | — | -12.1% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | 5.4% | — |
| Q3 25 | $1.33 | $-2.60 | ||
| Q3 24 | $-0.60 | $-0.09 | ||
| Q2 24 | $-0.68 | — | ||
| Q1 24 | $-0.53 | — | ||
| Q3 22 | $0.04 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $786.9M | $34.5M |
| Total DebtLower is stronger | — | $381.5M |
| Stockholders' EquityBook value | $1.1B | $130.5M |
| Total Assets | $1.2B | $947.9M |
| Debt / EquityLower = less leverage | — | 2.92× |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $786.9M | $34.5M | ||
| Q3 24 | $920.0M | $7.8M | ||
| Q2 24 | $701.7M | — | ||
| Q1 24 | $698.8M | — | ||
| Q3 22 | $386.2M | — |
| Q3 25 | — | $381.5M | ||
| Q3 24 | — | $31.5M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | — | — |
| Q3 25 | $1.1B | $130.5M | ||
| Q3 24 | $1.2B | $-1.3B | ||
| Q2 24 | $931.7M | — | ||
| Q1 24 | $935.3M | — | ||
| Q3 22 | $368.8M | — |
| Q3 25 | $1.2B | $947.9M | ||
| Q3 24 | $1.2B | $99.6M | ||
| Q2 24 | $973.7M | — | ||
| Q1 24 | $961.5M | — | ||
| Q3 22 | $410.9M | — |
| Q3 25 | — | 2.92× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.2M | $13.9M |
| Free Cash FlowOCF − Capex | $142.2M | $10.5M |
| FCF MarginFCF / Revenue | 68.4% | 6.9% |
| Capex IntensityCapex / Revenue | 0.0% | 2.2% |
| Cash ConversionOCF / Net Profit | 1.19× | — |
| TTM Free Cash FlowTrailing 4 quarters | $13.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $142.2M | $13.9M | ||
| Q3 24 | $-49.2M | $-1.5M | ||
| Q2 24 | $-32.9M | — | ||
| Q1 24 | $-43.8M | — | ||
| Q3 22 | $-24.2M | — |
| Q3 25 | $142.2M | $10.5M | ||
| Q3 24 | $-49.7M | $-6.1M | ||
| Q2 24 | $-33.9M | — | ||
| Q1 24 | $-45.1M | — | ||
| Q3 22 | $-25.3M | — |
| Q3 25 | 68.4% | 6.9% | ||
| Q3 24 | — | -2.6% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | -85.1% | — |
| Q3 25 | 0.0% | 2.2% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | 3.7% | — |
| Q3 25 | 1.19× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | -14.96× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IDYA
Segment breakdown not available.
XBP
| Related And Non Related Party | $136.5M | 90% |
| Technology | $8.2M | 5% |
| Other | $5.7M | 4% |
| Deferred Revenue As Of July312025 | $1.9M | 1% |
